Dividend Assets Capital LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 1.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,809 shares of the biopharmaceutical company’s stock after selling 505 shares during the period. Dividend Assets Capital LLC’s holdings in Pfizer were worth $1,152,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Norges Bank purchased a new stake in shares of Pfizer in the fourth quarter worth about $2,219,532,000. Morgan Stanley grew its stake in Pfizer by 16.4% in the fourth quarter. Morgan Stanley now owns 53,610,111 shares of the biopharmaceutical company’s stock worth $1,973,389,000 after purchasing an additional 7,540,245 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Pfizer by 12.1% during the 4th quarter. Bank of New York Mellon Corp now owns 64,756,839 shares of the biopharmaceutical company’s stock valued at $2,383,700,000 after purchasing an additional 6,965,496 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in Pfizer during the 4th quarter worth about $162,707,000. Finally, Sanders Capital LLC lifted its stake in Pfizer by 10.6% in the 4th quarter. Sanders Capital LLC now owns 31,947,816 shares of the biopharmaceutical company’s stock valued at $1,280,997,000 after buying an additional 3,051,838 shares in the last quarter. Institutional investors and hedge funds own 67.36% of the company’s stock.
A number of research analysts have weighed in on PFE shares. Morgan Stanley decreased their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Friday, January 29th. DZ Bank reiterated a “buy” rating and issued a $41.00 target price on shares of Pfizer in a report on Wednesday, February 3rd. TheStreet downgraded shares of Pfizer from a “b” rating to a “c+” rating in a report on Friday, March 5th. Mizuho dropped their price target on shares of Pfizer from $44.00 to $42.00 and set a “buy” rating for the company in a research note on Wednesday, February 3rd. Finally, SVB Leerink decreased their price objective on shares of Pfizer from $40.00 to $39.00 and set a “market perform” rating for the company in a research report on Thursday, April 1st. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $38.47.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.46 by ($0.04). Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The firm had revenue of $11.68 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same quarter in the previous year, the firm posted $0.55 earnings per share. Pfizer’s quarterly revenue was up 11.8% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 4th. Stockholders of record on Friday, May 7th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.90%. The ex-dividend date of this dividend is Thursday, May 6th. Pfizer’s payout ratio is 52.88%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.